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each monovalent antivenom,1,2 the specific
indications for first and repeat doses, and
the frequency and severity of immediate-
type and delayed hypersensitivity reactions.3
Snake envenoming is rare in Australia,
and because of the prevalence of cases in
Main
hype
react
Resu
cons
effecABSTRACT
Objective:  To investigate current use of Australian snake antivenoms and the frequency 
and severity of immediate-type hypersensitivity reactions.
Design:  Nested prospective cohort study as part of the Australian Snakebite Project.
Patients and setting:  Patients receiving snake antivenom in Australian hospitals 
between 1 January 2002 and 30 November 2007.
 outcome measures:  The use of CSL Limited antivenom; frequency and severity of 
rsensitivity reactions to antivenom; premedication and treatment of these 
ions.
lts:  Snake antivenom was administered to 195 patients, mostly for venom-induced 
umption coagulopathy (145 patients, 74%), followed by non-specific systemic 
ts (12%), neurotoxicity (5%) and myotoxicity (4%). Antivenom was given to nine 
patients (5%) without evidence of envenoming or who were bitten by a species of snake 
for which antivenom is not required. The commonest antivenoms used were brown 
snake (46%), tiger snake (30%) and polyvalent (11%). The median dose was four vials 
(interquartile range, 2–5 vials), and 24 patients received two different types of 
antivenom. Immediate-type hypersensitivity reactions occurred in 48 patients (25%); 21 
satisfied our definition of anaphylaxis, with 11 moderate and 10 severe cases, including 
nine in which patients were hypotensive. The remaining 27 reactions were mild (skin 
only). Adrenaline was used in 26 cases with good effect. The frequency of reactions to 
tiger snake (41%) and polyvalent (41%) antivenoms was higher than that to brown snake 
antivenom (10%). Hypersensitivity reactions occurred in 11 of 40 patients receiving any 
form of premedication (28%) and in 2 of 11 given adrenaline for premedication (18%) 
versus 20 of 86 not receiving premedication (23%).
Conclusions:  Antivenom was used appropriately, and most commonly for 
coagulopathy. Hypersensitivity reactions were common, but most were not severe. The 
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discretionary use of premedication was not associated with any reduction in reactions.nti
me
traA venom is the mainstay of treat-nt for snake envenoming. In Aus-lia, snake antivenoms have been
available for over 50 years and are regarded
as some of the most effective and safe
antivenoms. However, there remains signifi-
cant controversy over the dose required for
rural and regional Australia, and because no
one keeps records of snake bites across
Australia, it has been difficult to determine
actual numbers of cases each year, the
amount of antivenom used, the indications
for use and adverse reactions. Previous stud-
ies were mainly reviews of spontaneous
reporting to CSL Limited (Melbourne, Vic)
of antivenom use,4,5 single-hospital studies
or small or poorly designed retrospective
studies.6-9 These studies report reaction
rates to antivenom from zero to 54%, and
their definitions of anaphylaxis and allergy
have not been consistent. These disparate
results are problematic, and do not provide
useful information for guiding clinical care.
We aimed to investigate the current use of
antivenom and immediate hypersensitivity
reactions to antivenom in Australia through
a multicentre prospective study of snake
bites.
METHODS
The Australian Snakebite Project (ASP) is an
ongoing multicentre prospective study
which recruits cases of snake envenoming
from over 60 major tertiary and regional
hospitals, as well as referrals to all major
Australian poisons centres. Ethical approval
for this study was obtained from 16 human
research and ethics committees covering all
institutions involved in the study.
Patients’ demographic information, clin-
ical features of envenoming, laboratory
results, first aid and treatments are recorded
on a standardised study datasheet. Data-
sheets are supplied to the treating doctor at
the time of the bite, completed by hospital
staff and faxed or sent back to the investiga-
tors. Local investigators at some hospitals
maintain datasheets, and complete and fax
them back to the chief investigators. Cases
of snakebite are recruited mainly in the
emergency department or intensive care unit
within 24 hours of the bite. A small number
of cases (< 5%) are recruited after discharge
from hospital, and the same data collection
process is used. Faxed datasheets are
reviewed by the chief investigators or
trained research nurses to check data entry
and obtain medical records for missing
information. Data are then entered into a
purpose-built relational database by G K I.
Treatment is decided by the treating doctor,
but may be based on advice from a consult-
ant clinical toxicologist contacted about the
case.
Here, we describe a nested cohort of
patients who received antivenom, in order
to report the characteristics of snakebite
patients treated with antivenom, the fre-
quency and severity of immediate-type
hypersensitivity reactions to antivenom, and
treatment for antivenom anaphylaxis. All
patients recruited to the ASP between 1
January 2002 and 30 November 2007 were
included if they received CSL snake
antivenom. Specific information extracted
from our database for this analysis included:
patient demographic characteristics; clinical
features of  envenoming;  detail s  of
antivenom treatment (type and dose);
antivenom hypersensitivity reactions; pre-
medication; and treatment of antivenom
reactions. Patients were classified into five
groups by a single investigator, based on the
type and severity of envenoming as follows:
• Venom-induced consumption coagulo-
pathy, defined as an international normal-
ised ratio (INR) greater than 2.0 or
prothrombin time (PT) twice normal orMJA • Volume 188 Number 8 • 21 April 2008 473
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normal plus an elevated D-dimer level.
• Neurotoxicity, defined as at least ptosis
and including extra-ocular ophthalmo-
plegia, bulbar palsy, respiratory muscle
paralysis and limb paralysis.
• Myotoxicity, defined by local or general-
ised myalgia and/or muscle weakness in
association with a creatine kinase level
> 1000 U/L.
• Non-specific systemic features, defined
as at least three of nausea, vomiting, abdom-
inal pain, diarrhoea, diaphoresis and head-
ache.
• No objective evidence of envenoming
before the administration of antivenom, or
bite by an identified snake for which
antivenom is not indicated (eg, whip snake).
Immediate-type hypersensitivity reactions
were classified as mild, moderate or severe
(Box 1),10 based on the details recorded for
each allergic reaction in the database. If
patients received two types of antivenom,
only the first antivenom received was ana-
lysed because all but two reactions occurred
after the first dose of antivenom. Our defini-
tion of anaphylaxis was a moderate or severe
reaction according to this grading system,
which correlates closely with a recent inter-
national consensus definition of anaphyl-
axis.11 Treatment for each reaction was
recorded. For a subgroup of 126 patients
treated in larger centres that had an ASP
investigator based onsite, hospital notes
were available for us to perform a post-hoc
analysis of premedication use.
For descriptive statistics, median and inter-
quartile ranges (IQRs) were used for data not
normally distributed. Mathematica, version
5.2 (Wolfram Research, Inc, Champaign, Ill,
USA) was used for statistical analyses.
RESULTS
CSL snake antivenom was administered to
195 patients recruited to the ASP during the
study period of almost 6 years; 90% of these
patients received antivenom in the final 3
years of the study because of increased aware-
ness of the study among clinicians leading to
a higher recruitment rate. The median age of
the 195 patients was 41 years (IQR, 24–52
years), and 152 (78%) were male. The com-
monest reason for antivenom administration
was venom-induced consumption coagulo-
pathy (145 patients; 74%), followed by non-
specific systemic effects (12%), neurotoxicity
(5%) and myotoxicity (4%) (Box 2).
Antivenom was given to nine patients (5%)
without evidence of envenoming or who
were bitten by a species of snake where
antivenom treatment is not required. The
commonest antivenoms used were brown
snake and tiger snake antivenoms (Box 2).
The median antivenom dose was four vials
(IQR, 2–5 vials). Twenty-four patients
received two different types of antivenom —
nine were given polyvalent antivenom before
the snake was definitively identified, eight
were given polyvalent antivenom because
there was insufficient monovalent antivenom
or it was unavailable, and seven were given
the incorrect monovalent (6) or polyvalent
(1) antivenom.
Immediate-type al lergic reactions
occurred in 48 patients (25%); reactions
were mild in 27, moderate in 11 and severe
in 10 patients (Box 3). The commonest
feature was generalised erythema or urti-
caria (44 patients; 92%). Hypotension
(systolic blood pressure < 90 mmHg)
occurred in nine of the 10 severe cases.
Respiratory manifestations were uncom-
mon, with wheeze in seven patients, stridor
in one, and hypoxaemia in three. Adrenaline
was used for treatment in 26 cases of imme-
diate-type hypersensitivity reactions (54%).
There were no deaths attributed to allergic
reactions. Administration of antivenom was
not stopped (or was already complete) in 32
cases of reaction, was stopped and restarted
or slowed in 11 cases, and was stopped
when partially complete in five cases. Reac-
tions of any severity were most common
with tiger snake, polyvalent and death adder
antivenoms, and severe reactions occurred
with all of the three most commonly used
antivenoms. There was a statistically signifi-
cant difference between the frequencies of
reactions to different antivenoms (log-likeli-
hood ratio test, χ2 = 23.75; df = 5; P =
0.0002). The reaction occurred after the
first dose of antivenom in 46 of the 48 cases
and, in the two cases where a reaction
1 Grading system for generalised hypersensitivity reactions10
Grade* Description Definitive features
1 Mild (skin and subcutaneous 
tissues only)
Generalised erythema, urticaria, periorbital 
oedema, or angioedema
2 Moderate (features suggesting 
respiratory, cardiovascular or 
gastrointestinal involvement)
Dyspnoea, stridor, wheeze, nausea, vomiting, 
dizziness (presyncope), diaphoresis, chest or throat 
tightness, or abdominal pain
3 Severe (hypoxia, hypotension, 
or neurological compromise)
Cyanosis or SpO2  92% at any stage, hypotension 
(systolic blood pressure, < 90 mmHg in adults), 
confusion, collapse, loss of consciousness, or 
incontinence
SpO2 = oxygen saturation as measured by pulse oximetry. 
* The moderate and severe grades approximate the National Institute of Allergy and Infectious Disease/Food 
Allergy and Anaphylaxis Network definition of anaphylaxis.11 ◆
2 Indications for antivenom and types of antivenom used
Antivenom used
Major indication
No. of 
patients
Brown 
snake
Tiger 
snake Black snake Taipan
Death 
adder Polyvalent Sea snake
Venom-induced consumption coagulopathy 145 83 43 — 5 — 14 —
Non-specific systemic effects 23 2 12 6 — — 3 —
Neurotoxicity 10 — — — — 9 1 —
Myotoxicity 8 — 2 4 — — 1 1
No apparent indication/non-envenomed 9 4 2 — — — 3 —
Total 195 89 59 10 5 9 22 1474 MJA • Volume 188 Number 8 • 21 April 2008
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received only one type of antivenom.
Information was available on premedica-
tion use in 126 patients. Forty of these
received premedication, with 11 patients
receiving adrenaline, 17 receiving prometh-
azine and 27 receiving hydrocortisone. Of
these, 11 received both promethazine and
hydrocortisone, three received both adrena-
line and hydrocortisone, and one was given
all three agents. Immediate-type hypersensi-
tivity reactions occurred in 11 of 40 patients
receiving any form of premedication (28%),
two of 11 patients receiving adrenaline
(18%) and 20 of 86 patients who did not
receive premedication (23%). Two patients
appeared to have immediate-type allergic
reactions to venom with clinical effects of
allergy manifesting before antivenom
administration. Both were snake handlers
who had had previous snake bites, and both
were bitten by taipans.
DISCUSSION
Antivenom is mainly used in Australia to
treat venom-induced consumption coagulo-
pathy, with less than 10% being used for
neurotoxicity and myotoxicity combined.
Antivenom was used in only a small number
of patients without signs of envenoming,
suggesting that most antivenom in Australia
is being used appropriately. The rate of
immediate-type hypersensitivity reactions to
antivenom is higher than we would have
expected from most previous reports (Box
4), but is consistent with other antivenoms
containing F(ab´)2 immunoglobulin frag-
ments internationally.12 Severe reactions
were uncommon and characterised mainly
by hypotension. Skin reactions occurred in
almost all cases and respiratory effects were
uncommon. Antivenom therapy was com-
pleted in most cases, and there were no
fatalities associated with antivenom use. Pre-
medication was administered in a small
proportion of patients, but was not associ-
ated with a reduction in the reaction rate
(although there may have been selection
bias as high-risk patients may have been
more likely to receive premedication).
The rate of antivenom reactions has varied
in previous studies from no reactions being
reported in one small retrospective study6 to
54% and 39% reported in two early studies
from Papua New Guinea (Box 4) by Camp-
bell.13,14 None of these studies clearly
defined immediate-type hypersensitivity
reactions and, in most, it is difficult to
determine the frequency of severe reactions
(Box 4).4-7,9,13-16 The higher rate of any
immediate-type hypersensitivity reactions in
Campbell’s studies may reflect a degree of
better ascertainment than other studies, as
Campbell observed and managed the
patients himself, rather than relying on data
from questionnaires or retrospective review
of cases.13,14 Campbell noted that some of
the reactions were transient and could only
be recorded if the patient was closely
observed. The frequency of severe reactions
reported by Campbell and others was
low,4,13,14,16 and similar to that in our study.
It is difficult to interpret the differing
frequencies of reactions to the various
monovalent antivenoms. We have previ-
ously reported a high frequency of reactions
to tiger snake antivenom,17 which is sup-
ported by this larger study. However, the
large difference in frequencies of reactions to
tiger and brown snake antivenoms is diffi-
cult to reconcile with the fact that the
antivenoms are, in fact, polyvalent. This has
been confirmed recently in a study showing
that brown and tiger snake antivenoms are
mixtures, and neutralise and bind to both
brown and tiger snake venoms.18
The use of premedication was dictated by
the treating doctor, and adrenaline,
promethazine and corticosteroids were used
or  in varying combinations. Statistical com-
parisons between various different premedi-
cation regimens was not possible, but there
appeared to be no association between
adrenaline (alone or in combination) or
other premedication and immediate-type
3 Frequency of immediate-type hypersensitivity reactions and anaphylaxis for 
each snake antivenom
Antivenom
No. of patients 
receiving 
antivenom
No. of patients (%)
with immediate-type 
hypersensitivty reactions
Anaphylaxis
Mild Moderate Severe
Brown snake 89 9 (10%) 3 3 3
Tiger snake 59 24 (41%) 13 5 6
Black snake 10 1 (10%) — 1 —
Death adder 9 4 (44%) 4 — —
Taipan 5 1 (20%) 1 — —
Polyvalent 22 9 (41%) 6 2 1
4 Summary of previous studies of acute allergic reactions from Australasian snake antivenoms
Study
Total no. 
of cases Study design
Antivenom 
reaction
Severe 
anaphylaxis*
Trinca, 19634 100 Retrospective; spontaneous reports of antivenom use 8 (8%) 3 (3%)
Campbell, 196413 39 Unclear methods 21 (54%) 1 (3%)
Campbell, 196714 28 Collection of cases; unclear methods 11 (39%) 1 (4%)
Sutherland and Lovering, 19798 181 Spontaneous reports to manufacturer with retrospective follow-up by mail 19 (10%) 6 (3%)
Sutherland, 199215 86 Spontaneous reports to the manufacturer 4 (5%) 0 (0)
Jamieson and Pearn, 198916 14 Retrospective study of children 3 (21%) 1 (7%)
Tibballs, 19926 12 Retrospective study of children 0 (0) 0 (0)
Barret and Little, 20037 20 Retrospective study 3 (15%) Not recorded
Williams et al, 20079 136 Retrospective study of rural health centre records 25 [13]† (18%) [10%] 7 (5%)
* This is a subgroup of all patients with reactions. † Only 13 of the 25 cases reported by the authors meet the definition of allergy (Box 1) and include non-specific 
features such as tachycardia, hypertension, pyrexia and tachypnoea without features typical of allergy. ◆MJA • Volume 188 Number 8 • 21 April 2008 475
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interpreted with caution because our study
was not designed to test the effect of pre-
medication. While a recent study from
Papua New Guinea suggested that adrena-
line premedication was effective, the study
was retrospective, did not use a standard
definition for allergic reactions and used
selective statistical analysis that did not cor-
rect for multiple comparisons.9 Of the 25
cases reported as immediate-type allergic
reactions in this study, only 13 met the
definition of allergy (Box 1), and urticaria
was reported in only six cases. The low rate
of immediate-type allergic reactions (13 of
136 or 10%) and the rarity of skin manifest-
ations suggests that the retrospective nature
of the study caused cases to be missed,
casting further doubt on the validity of its
conclusions on premedication.9
A limitation of our study was that
antivenom infusion rates, which may be an
important determinant of whether a reaction
occurs, could not be accurately determined.
This was in part because of the differing
volumes of protein in each type of
antivenom. More problematic was the fact
that our study reported the total duration of
antivenom administration and it was
unclear if this duration included stopping
and restarting the antivenom infusion or just
the initial infusion rate.
In summary, Australian snake venoms are
currently being used appropriately and
mainly for coagulopathy. Immediate-type
hypersensitivity reactions occur in a quarter
of patients, and severe hypotensive reactions
in 5%. The low incidence of severe reac-
tions, satisfactory response to resuscitation,
and lack of an association between discre-
tionary use of premedication and reactions
supports the current approach of most clini-
cians, who do not use premedication rou-
tinely.
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